Drugs / NNC 0151-0000-0000
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01018238 | Nov 2009 | systemic lupus erythematosus | Novo Nordisk A/S | Withdrawn | No outcome recorded |
| Phase 1 | NCT02151409 | Jun 2008 → Oct 2009 | rheumatoid arthritis, systemic lupus erythematosus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01223911 | Jan 2011 → Feb 2013 | rheumatoid arthritis | Novo Nordisk A/S | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NNC 0151-0000-0000 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02151409 ↗ |
| Known as | NNC 151-0000-0000 | “The aim of this clinical trial is to investigate the safety, tolerability, pharmacokinetics and signs of bioactivity of increasing repeated doses of NNC 151-0000-0000 in...” NCT01018238 ↗ |
| Modality | Other / unclassified | “Anti-C5a Receptor Antibody (NNC 0151-0000-0000)” NCT01018238 ↗ |
| Route | Subcutaneous | “Multiple doses in the range of 0.05mg/kg to 0.30mg/kg administered subcutaneously (under the skin)” NCT01018238 ↗ |